Rhonda Rhyne has deep industry experience in medical technology and machine learning, a subset of AI. She has more than 25 years’ experience as an executive and board director developing and commercializing disruptive medical technologies. Ms. Rhyne led two start-ups companies to rapid growth including CardioDynamics, a publicly-traded medical device company, which was sold to SonoSite FujiFilm.
Rhonda has been recognized as an industry leader including Ernst & Young Entrepreneur of the Year – Medical Products and Deloitte’s Fast 50 Award for 50 Fastest Growing Tech/Life Science Companies in Southern California for 9 years from 1999–2007.
Currently, Rhonda is President, CEO, and Board Director for Prevencio, Inc., a cardiac biomarker company developing novel Artificial Intelligence (AI)-driven, multi-protein in vitro diagnostic and prognostic tests for cardiovascular disease. Prevencio is also in partnerships with Microsoft and Seattle Children’s Hospital (for custom diagnostics for Kawasaki Disease).
Rhonda also serves on the Board of Directors for Aminex Therapeutics and Life Science Washington. She earned an MBA from the UCLA Anderson School of Business Administration and a bachelor’s degree in Pharmacy from Washington State University. She has also authored a leadership book, Keys to the Corner Office: Success Strategies for Women by Women.